Fujian Haixi Pharmaceuticals Co., Ltd.

福建海西新药创制股份有限公司

02637.HK

Commercial-stage pharmaceutical company in China integrating R&D, production and sales of generic drugs for digestive, cardiovascular, endocrine, nervous system and inflammatory diseases, with a pipeline of in-house innovative candidates including oncology and retinal disease therapies.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Distribution model
• Government or SOE customers and tenders
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Inventory level and ageing
• Investments and fair-value assets
• Related-party transactions and balances
• Other